Sangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/16/23
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This WeekThe Motley Fool • 02/10/23
Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023Seeking Alpha • 11/20/22
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial ResultsBusiness Wire • 11/03/22
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and WebcastBusiness Wire • 10/27/22
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine PatientsBusiness Wire • 10/12/22
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated PatientsBusiness Wire • 08/30/22
Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect?Zacks Investment Research • 08/29/22
Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should KnowZacks Investment Research • 08/12/22
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/04/22
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial ResultsBusiness Wire • 08/04/22
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and WebcastBusiness Wire • 07/28/22
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ TransplantationBusiness Wire • 07/21/22
Sangamo Therapeutics Announces Participation at Upcoming Investor ConferencesBusiness Wire • 06/01/22
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial ResultsBusiness Wire • 05/05/22
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business Wire • 05/02/22
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and WebcastBusiness Wire • 04/28/22
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 04/04/22